Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nina Long
Staff Scientist
Nova Research, Inc.
Current research includes
Development of a portable bead-based Microflow Cytometer assay for persistant sensing of sepsis targets.
Dialysis-like therapeutics using Raman surface enhanced resonance spectroscopy with antimicrobial peptides.
DARPA-SN-12-05 Amendment 01
DARPA MTO
Dialysis Like Therapeutics (DLT)
Technology Exchange
Arlington, VA
The Defense Advanced Research Projects Agency (DARPA) Microsystems Technology Office (MTO) will
conduct a briefing in support of the anticipated Broad Agency Announcement (BAA) for the integration
portion of the Dialysis Like Therapeutics (DLT) program. When released, the BAA will be posted on the
Federal Business Opportunities (FBO) website, http://www.fedbizopps.gov ; and the Grants.gov website,
http://www.grants.gov. This Technology Exchange workshop is unclassified. ;
Attendance at the DLT Technology Transfer Day is voluntary and is not required to propose to
subsequent BAAs (if any) on this topic. The Technology Exchange Day workshop does not constitute a
formal solicitation for proposals or abstracts. This announcement is issued solely for information and
program planning purposes and is not a Request for Information (RFI). Since this is not an RFI, no
submissions against this notice will be accepted by the Government. DARPA will not provide
reimbursement for costs incurred to participate in this workshop. Interested parties to this notice are
cautioned that nothing herein obligates the Government to issue a solicitation.
BACKGROUND
The goal of DARPA’s Dialysis Like Therapeutics program is to develop a portable device that removes
“dirty” blood from the body, separates harmful agents, and returns “clean” blood to the body in a
manner similar to dialysis treatment of kidney failure. While the device could have an impact across
multiple areas of medicine, the target application for this device is sepsis.
The envisioned system will be capable of removing at least 90% of unknown pathogens, cytokines,
toxins, and activated cells from a patient in one day with the objective of significantly reducing patient
mortality. At the completion of the program the device will be submitted to the Food and Drug
Administration (FDA) for possible Investigational Device Exemption (IDE) status.
In the initial DLT solicitation, DARPA-BAA-11-30, DARPA sought innovative proposals to develop and
apply scientific advances in the design of system components for a blood sensing and purification
device. Fundamental to the success of DLT is the integration of the system components currently being
developed into a portable device. As stated in the initial DLT solicitation, system integrators will be
responsible for managing the life-cycle system integration process that includes system design,
integration, validation, regulatory approval, and demonstrations throughout the program. It also stated
that proposers for system integration are required to develop intellectual property agreements with
component developers. Therefore, meeting participants could include technical, business development,
and contracting personnel from teams considering submission to potential future solicitations.
This Special Notice serves as an announcement for a Technology Exchange workshop. The objective of
the workshop will be to familiarize interested parties with the DLT component technologies, discuss
potential scientific requirements for integration proposals, and examine award instrument types and
funding options for the forthcoming Integration Broad Agency Announcement (BAA).
PURPOSE
The purpose of the DLT Technology Transfer workshop is threefold:
1. To familiarize participants with DARPA’s interest in integrating DLT related component technologies
into a device.
2. To identify potential proposers and promote understanding of the anticipated DLT BAA proposal
requirements; and
3. To promote discussion of synergistic capabilities among potential program participants.
It is DARPA’s desire to receive comprehensive, quality responses to the anticipated DLT BAA. To assist
those wanting to form strong, collaborative teaming efforts and business relationships, a teaming
website (http://teaming.sysplan.com/BAA-11-30/) ; exists to facilitate formation of teaming
arrangements between interested parties. Specific content, communications, networking, and team
formation are the sole responsibility of the participants. Neither DARPA nor the Department of Defense
endorses the destination website or the information and organizations contained therein. This website
is provided consistent with the stated purpose of the anticipated DLT BAA.
Additional information regarding the DLT BAA will be available at
http://www.darpa.mil/Opportunities/Solicitations/DARPA_Solicitations.aspx#MTO ; following the
publication of the BAA on FBO. It is anticipated that the DLT BAA will be released in early April 2012. If a
BAA is released, materials presented at the workshop, as well as a frequently asked questions (FAQ)
document compiling questions and answers received to date, may be made available at the website
mentioned above.
TENTATIVE AGENDA
Event will be held on Thursday, March 29, 2012
The event will take place at The Capital Conference Center on the 6th floor at System Planning
Corporation (3601 Wilson Boulevard, Arlington, VA 22201).
Registration/Light Breakfast: 0800-0900 EDT
Presentations/Discussions: 0900-1600 Eastern
REGISTRATION INFORMATION
? Interested parties must send an email to DARPA-SN-12-05@darpa.mil and request to be added to
the registration website. No media will be allowed.
? Interested parties will then be able to register for the Technology Transfer workshop at
https://safe.sysplan.com/mto/dlt_transfer. This website is operational. ;
? Registration must be completed by COB March 9, 2012.
? Non-U.S. citizens are required to submit a DARPA Form 60 to the registration website no later than
COB March 9, 2012. Submission instructions will be sent in the registration receipt e-mail.
? All attendees will be required to present Government-issued photo identification upon entry to the
event.
? There will NOT be a registration fee for this event.
Questions regarding this notice should be directed to: DARPA-SN-12-05@darpa.mil
DARPA-SN-12-05
DARPA MTO
Dialysis Like Therapeutics (DLT)
Technology Exchange
Arlington, VA
The Defense Advanced Research Projects Agency (DARPA) Microsystems Technology Office (MTO) will conduct a briefing in support of the anticipated Broad Agency Announcement (BAA) for the integration portion of the Dialysis Like Therapeutics (DLT) program. When released, the BAA will be posted on the Federal Business Opportunities (FBO) website, http://www.fedbizopps.gov and the Grants.gov website, http://www.grants.gov. This Technology Exchange workshop is unclassified.
Attendance at the DLT Technology Transfer Day is voluntary and is not required to propose to subsequent BAAs (if any) on this topic. The Technology Exchange Day workshop does not constitute a formal solicitation for proposals or abstracts. This announcement is issued solely for information and program planning purposes and is not a Request for Information (RFI). Since this is not an RFI, no submissions against this notice will be accepted by the Government. DARPA will not provide reimbursement for costs incurred to participate in this workshop. Interested parties to this notice are cautioned that nothing herein obligates the Government to issue a solicitation.
BACKGROUND
The goal of DARPA’s Dialysis Like Therapeutics program is to develop a portable device that removes “dirty” blood from the body, separates harmful agents, and returns “clean” blood to the body in a manner similar to dialysis treatment of kidney failure. While the device could have an impact across multiple areas of medicine, the target application for this device is sepsis.
The envisioned system will be capable of removing at least 90% of unknown pathogens, cytokines, toxins, and activated cells from a patient in one day with the objective of significantly reducing patient mortality. At the completion of the program the device will be submitted to the Food and Drug Administration (FDA) for possible Investigational Device Exemption (IDE) status.
In the initial DLT solicitation, DARPA-BAA-11-30, DARPA sought innovative proposals to develop and apply scientific advances in the design of system components for a blood sensing and purification device. Fundamental to the success of DLT is the integration of the system components currently being developed into a portable device. As stated in the initial DLT solicitation, system integrators will be responsible for managing the life-cycle system integration process that includes system design, integration, validation, regulatory approval, and demonstrations throughout the program. It also stated that proposers for system integration are required to develop intellectual property agreements with component developers. Therefore, meeting participants could include technical, business development, and contracting personnel from teams considering submission to potential future solicitations.
This Special Notice serves as an announcement for a Technology Exchange workshop. The objective of the workshop will be to familiarize interested parties with the DLT component technologies, discuss potential scientific requirements for integration proposals, and examine award instrument types and funding options for the forthcoming Integration Broad Agency Announcement (BAA).
PURPOSE
The purpose of the DLT Technology Transfer workshop is threefold:
1. To familiarize participants with DARPA’s interest in integrating DLT related component technologies into a device.
2. To identify potential proposers and promote understanding of the anticipated DLT BAA proposal requirements; and
3. To promote discussion of synergistic capabilities among potential program participants.
It is DARPA’s desire to receive comprehensive, quality responses to the anticipated DLT BAA. To assist those wanting to form strong, collaborative teaming efforts and business relationships, a teaming website (http://teaming.sysplan.com/BAA-11-30/) exists to facilitate formation of teaming arrangements between interested parties. Specific content, communications, networking, and team formation are the sole responsibility of the participants. Neither DARPA nor the Department of Defense endorses the destination website or the information and organizations contained therein. This website is provided consistent with the stated purpose of the anticipated DLT BAA.
Additional information regarding the DLT BAA will be available at http://www.darpa.mil/Opportunities/Solicitations/DARPA_Solicitations.aspx#MTO following the publication of the BAA on FBO. It is anticipated that the DLT BAA will be released in early April 2012. If a BAA is released, materials presented at the workshop, as well as a frequently asked questions (FAQ) document compiling questions and answers received to date, may be made available at the website mentioned above.
TENTATIVE AGENDA
Registration: 0800-0900 EDT
Presentations/Discussions: 0900-1700 Eastern
*Date of the meeting is to be determined; plan for March 28 or 29, 2012.
REGISTRATION INFORMATION
• Interested parties must register for the Technology Transfer workshop at https://safe.sysplan.com/mto/dlt_transfer. This website will not be operational until 2012.
• Registration must be completed by COB March 9, 2012.
• Non-U.S. citizens are required to submit a DARPA Form 60 to the registration website no later than COB March 9, 2012. Submission instructions will be sent in the registration receipt e-mail.
• All attendees will be required to present Government-issued photo identification upon entry to the event.
• There will be a registration fee for this event.
Questions regarding this notice should be directed to : DARPA-SN-12-05@darpa.mil
The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007
(I am reposting this because of the reference to baby boomers. It is surprising that HCV has a high mortality in that age group)
Background: The increasing health burden and mortality from hepatitis B virus (HBV) and hepatitis C virus (HCV) in the United States are underappreciated.
Objective: To examine mortality from HBV; HCV; and, for comparison, HIV.
Design: Analysis of U.S. multiple-cause mortality data from 1999 to 2007 from the National Center for Health Statistics.
Setting: All U.S. states and the District of Columbia.
Participants: Approximately 22 million decedents.
Measurements: Age-adjusted mortality rates from HBV, HCV, and HIV. Logistic regression analyses of 2007 data generated 4 independent models per outcome (HCV- or HBV-related deaths) that each included 1 of 4 comorbid conditions and all sociodemographic characteristics.
Results: Between 1999 and 2007, recorded deaths from HCV increased significantly to 15 106, whereas deaths from HIV declined to 12 734 by 2007. Factors associated with HCV-related deaths included chronic liver disease, HBV co-infection, alcohol-related conditions, minority status, and HIV co-infection. Factors that increased odds of HBV-related death included chronic liver disease, HCV co-infection, Asian or Pacific Islander descent, HIV co-infection, and alcohol-related conditions. Most deaths from HBV and HCV occurred in middle-aged persons.
Limitation: A person other than the primary physician of the decedent frequently completed the death certificate, and HCV and HBV often were not detected and thus not reported as causes of death.
Conclusion: By 2007, HCV had superseded HIV as a cause of death in the United States, and deaths from HCV and HBV disproportionately occurred in middle-aged persons. To achieve decreases in mortality similar to those seen with HIV requires new policy initiatives to detect patients with chronic hepatitis and link them to care and treatment. Primary Funding Source: Centers for Disease Control and Prevention.
Future Directions for NIAID HIV Research: Consider and Comment
http://blog.aids.gov/2010/08/future-directions-for-niaids-hiv-vaccine-clinical-research-consider-and-comment.html
HELP-4-HEP
http://www.help4hep.org/
Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients
Journal of Hepatology
January 2012
Hepatitis C virus (HCV) coinfection is one of the leading causes of mortality in human immunodeficiency virus-infected patients. The current standard of care leads to cure only in a part of these patients. The course of the disease is determined by the rapidity of liver fibrosis progression (LFP). The influence of interferon on LFP in coinfected patients has yet not been evaluated by comparative liver biopsies.
Conclusions
HCV treatment can stop fibrosis progression and induce its regression. Nonresponders to treatment may even have a fast fibrosis progression. It remains to be clarified if the same factors that induce nonresponse to treatment may also induce faster fibrosis progression.
Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of Interferon-Free (All-Oral) Treatment Regimen of INCIVEK®, VX-222 and Ribavirin in People with Genotype 1 Hepatitis C
http://investors.vrtx.com/releasedetail.cfm?ReleaseID=650944
Economic burden of hepatitis C-associated diseases in the United States
Authors: El Khoury, A. C.1; Klimack, W. K.2; Wallace, C.2; Razavi, H.2
Source: Journal of Viral Hepatitis, 1 March 2012
Summary. There are approximately 100 drugs in development to treat hepatitis C. Over the next decade, a number of new therapies will become available. A good understanding of the cost of hepatitis C sequelae is important for assessing the value of new treatments. The objective of this study was to assess the economic burden data sources for hepatitis C in the United States. A systematic literature search was conducted to identify studies reporting the costs of hepatitis C sequelae in the United States. Over 400 references were identified, of which 50 were pertinent. The costs were compiled and adjusted to 2010 constant US dollars using the medical component of the consumer price index (CPI). The cost of liver transplants was estimated at $201 110 ($178 760-$223 460), hepatocellular carcinoma (HCC) at $23 755-$44 200, variceal haemorrhage at $25 595, compensated cirrhosis at $585-$1110, refractory ascites at $24 755, hepatic encephalopathy at $16 430, sensitive ascites at $2450, moderate chronic hepatitis C at $155, and mild chronic hepatitis C at $145 per year per person. All studies were traced back to a handful of publications in the 1990s, which have provided the basis for all sequelae-based cost estimates to date. Hepatitis C imposes a high economic burden. Most cost analysis is more than 10 years old, and more research is required to update the sequelae costs associated with HCV infection.
African Americans and the National HIV/AIDS Strategy
http://blog.aids.gov/2012/02/african-americans-and-the-national-hivaids-strategy.html
Reducing Viral Hepatitis Disparities Among African Americans
http://blog.aids.gov/2012/02/reducing-viral-hepatitis-disparities-among-african-americans.html
Making History: Eliminating Viral Hepatitis Disparities in the African American Community
http://blog.aids.gov/2012/02/making-history-eliminating-viral-hepatitis-disparities-in-the-african-american-community.html
Less then half of the people with HIV Not Receiving Regular Care
Background: Monitoring immunologic and virologic response to antiretroviral therapy in HIV-1-infected patients is an important component of treatment in the United States. However, little population-based information is available on whether HIV-infected persons receive the recommended tests or continuous care
Results: Among 100,375 persons living with HIV, 45% had >=2 tests at least 3 months apart. A higher percentage of whites was retained in care (50%) compared with blacks/African Americans (41%, PR 0.83, 95% CI 0.82, 0.84) and Hispanics/Latinos (40%, PR 0.90, 95% CI 0.87, 0.92). Compared with heterosexual women (50%), fewer men who have sex with men (48%), heterosexual males (45%), and male (37%) and female (43%) injection-drug users had >=2 tests. About 64% established care within 12 months of diagnosis.
Conclusions: Less than half of persons living with HIV had laboratory evidence of ongoing clinical care and only two-thirds established care after diagnosis. Further assessments determining modifiable barriers to accessing care could assist with achieving public health targets.
Hall, H Irene PhD, MPH; Gray, Kristen Mahle MPH; Tang, Tian; Li, Jianmin DPE; Shouse, Luke MD, MPH; Mermin, Jonathan MD, MPH
New Blood Test Detects Cancer at a Very Early Stage (This is a distant shot - but maybe such a test can be combined with the exosome ELLSA essay. I only mention this because the DARPA initiative for DLT did mention exosome removal as a potential therapeutic benefit of the device.)
http://www.aabgu.org/media-center/bgu-making-a-difference/blood-test-cancer.html
Benefits of hepatitis C treatment outweigh costs for patients with advanced disease, study shows
http://med.stanford.edu/ism/2012/february/hepatitis.html
hotdog1012,
I meant - please send me an email with your personal email I can respond to!
hotdog1012
If you have premium membership on ihub, can you send me a private message?
The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007
Kathleen N. Ly, MPH; Jian Xing, PhD; R. Monina Klevens, DDS, MPH; Ruth B. Jiles, PhD, MPH; John W. Ward, MD; and Scott D. Holmberg, MD, MPH
+ Author Affiliations
From the Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
Background: The increasing health burden and mortality from hepatitis B virus (HBV) and hepatitis C virus (HCV) in the United States are underappreciated.
Objective: To examine mortality from HBV; HCV; and, for comparison, HIV.
Design: Analysis of U.S. multiple-cause mortality data from 1999 to 2007 from the National Center for Health Statistics.
Setting: All U.S. states and the District of Columbia.
Participants: Approximately 22 million decedents.
Measurements: Age-adjusted mortality rates from HBV, HCV, and HIV. Logistic regression analyses of 2007 data generated 4 independent models per outcome (HCV- or HBV-related deaths) that each included 1 of 4 comorbid conditions and all sociodemographic characteristics.
Results: Between 1999 and 2007, recorded deaths from HBV increased significantly to 15 106, whereas deaths from HIV declined to 12 734 by 2007. Factors associated with HCV-related deaths included chronic liver disease, HBV co-infection, alcohol-related conditions, minority status, and HIV co-infection. Factors that increased odds of HBV-related death included chronic liver disease, HCV co-infection, Asian or Pacific Islander descent, HIV co-infection, and alcohol-related conditions. Most deaths from HBV and HCV occurred in middle-aged persons.
Limitation: A person other than the primary physician of the decedent frequently completed the death certificate, and HCV and HBV often were not detected and thus not reported as causes of death.
Conclusion: By 2007, HCV had superseded HIV as a cause of death in the United States, and deaths from HCV and HBV disproportionately occurred in middle-aged persons. To achieve decreases in mortality similar to those seen with HIV requires new policy initiatives to detect patients with chronic hepatitis and link them to care and treatment.
Primary Funding Source: Centers for Disease Control and Prevention.
texe,
I have not kept up with the latest O/S structure, at least not over the past 2-3 months. If I do come across any info. I shall post it.
Gilead Announces Data for Genotype 1 Null Responder Hepatitis C Patients Enrolled in ELECTRON Study
http://www.gilead.com/pr_1662331
Open innovation in Pharmaceutical R & D -
http://pharma.flemingeurope.com/innovation-pharma-rd/
Making History: Eliminating Viral Hepatitis Disparities in the African American Community
http://blog.aids.gov/2012/02/making-history-eliminating-viral-hepatitis-disparities-in-the-african-american-community.html?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+aids%2Fgov+%28Blog.AIDS.gov%29&utm_content=Yahoo%21+Mail
President’s Budget Request Reflects Strong Commitment on Global AIDS
POSTED BY ERIC GOOSBY / FEBRUARY 13, 2012
http://blogs.state.gov/index.php/site/entry/budget_global_aids
Fighting the HIV/AIDS Epidemic and Supporting People Living with HIV/AIDS
http://www.whitehouse.gov/omb/factsheet/fighting-the-HIV-AIDS-epidemic-and-supporting-people-living-with-HIV-AIDS
President’s FY 2013 Budget Supports Implementation of the National HIV/AIDS Strategy
On Monday, President Obama sent his Fiscal Year 2013 budget proposal to Congress. The budget proposal clearly demonstrates his determination to help the Nation achieve the goals of the National HIV/AIDS Strategy (NHAS) and renews the President’s commitment to ending the AIDS pandemic. To address HIV/AIDS in the U.S., the 2013 Budget:
Supports HIV/AIDS research.
Expands investments in prevention and care.
Funds cross-cutting innovative efforts for care and prevention.
Expands the Ryan White HIV/AIDS Program.
Increases funding for HIV/AIDS prevention and service integration.
Modernizes the Housing Opportunities for Persons with AIDS (HOPWA) Program.
Fights the stigma of HIV/AIDS.
Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: NHANES 2001-08†
Many persons infected with hepatitis C virus (HCV) are unknown to the healthcare system because they may be asymptomatic for years, have not been tested for HCV infection, and only seek medical care when they develop liver-related complications. We analyzed data from persons who tested positive for past or current HCV infection during participation in the National Health and Nutrition Examination Survey (NHANES) from 2001 through 2008. A Follow-up Survey was conducted six months after examination to determine: 1) how many participants testing positive for HCV infection were aware of their HCV status before being notified by NHANES, 2) what actions participants took after becoming aware of their first positive test, and 3) participants' knowledge about hepatitis C. Of 30,140 participants tested, 393 (1.3%) had evidence of past or current HCV infection; 170 (43%) could be contacted during the follow-up survey and interviewed. Only 49.7% were aware of their positive HCV infection status before being notified by NHANES, and only 3.7% of these respondents reported that they had first been tested for HCV because they or their doctor thought they were at risk for infection. Overall, 85.4% had heard of hepatitis C; correct responses to questions about hepatitis C were higher among persons aged 40-59 years, white non-Hispanics, and respondents who saw a physician after their first positive HCV test. Eighty percent of respondents indicated they had seen a doctor about their first positive HCV test result.
Conclusion:
These data indicate that fewer than half of those infected with HCV may be aware of their infection. The findings suggest that more intensive efforts are needed to identify and test persons at risk for HCV infection. (Hepatology 2011.)
Hepatology
Maxine M Denniston MSPH1,‡,*, Klevens R Monina MPH, DDS1, Geraldine M McQuillan PhD2, Ruth B Jiles MS, MPH, PhD1
What Is Killing People with Hepatitis C Virus Infection?
The burden of hepatitis C virus (HCV)-related morbidity and mortality continues to rise. Progression to advanced liver disease among HCV-infected individuals generally requires decades, but we are entering an era where those infected with HCV in the 1970s and 1980s are at significant risk of mortality. Liver disease has overtaken drug-related harm as the major cause of mortality in HCV-infected individuals in many settings. Direct-acting antiviral therapies have provided renewed optimism, but HCV treatment uptake will need to increase markedly to reduce liver disease mortality. This review provides updated information on the natural history of HCV, disease-specific causes of mortality among people with HCV, estimates and projections of HCV-related disease burden and mortality and individual and population-level strategies to reduce mortality. The considerable variability in mortality rates within subpopulations of people with HCV will be outlined, such as in people who inject drugs and those with HIV co-infection.
Jason Grebely1, Gregory J. Dore1
1 Viral Hepatitis Clinical Research Program, The Kirby Institute for Infection and Immunity in Society, The University of New South Wales, Sydney, Australia
Diagnostics for viruses a step closer to reality
http://www.leeds.ac.uk/news/article/2951/diagnostics_for_viruses_a_step_closer_to_reality
hotdog1012,
"civilian deaths because of sepsis in 2009 with the number being 215,000 and the associated cost - 16.7B. The goal is to save atleast 43,000 US lives and $3.3B annually"!!! This is from the DARPA DLT presentation.
AEMD has potential blockbuster applications with at least Sepsis and HCV. What surprises me is that Fresenius has not jumped in so far. Fresenius seems to be the one which would capitalize the earliest with AEMD, with the internationally ready infrastructure and the huge R&D they possess. I think that would be a scary scenario to other pharmas.
kismetkid
I have been extremely busy over the past 2 months. As a result I have been posting sparingly.
Honestly, I only superficially glanced through the latest PR! My opinion from what I have read is that the numbers are strong though not surprising, if one is familiar with the HP. Also, AEMD has given out more scientific info. about the trial which maybe a good thing for both the medical community and more importantly big pharmas. International companies are well aware of the AEMD - the question they need to be asked is just like with the FDA - what would they like to see in AEMD which would make it an attractive partner for them. At one time I thought AEMD could take on the field alone - but seeing the tremendous advances in anti HCV meds, my feeling is that if AEMD is not brought to the forefront soon, the opportunity may not be the same within a few years. And to do so big backing may be essential. It has still a lot going for it including the obvious DARPA sepsis project, but again, sepsis and cancer applications are still in the investigational/early stages.
I am very impressed with how JJ has been guiding this company. There has to be a tremendous amount of hard work going on in the background which we shall never know of.
Aethlon Medical Reports Immediate and Rapid Virologic Responses in Hepatitis C (HCV) Patients Receiving Hemopurifier® Treatment Protocol PR Newswire07:33am EST
http://finance.yahoo.com/news/Aethlon-Medical-Reports-prnews-2296001423.html?x=0
An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region
Liver International, 01/19/2012 Clinical Article
Nakano T et al. – This updated analysis based on the complete region of hepatitis C virus (HCV) confirmed the validity of the previously assigned genotypes/subtypes and provided an up–to–date reference for future basic research and clinical studies.
Methods
•All available HCV complete genome sequences in the HCVdatabases available through October 2010 were analyzed.
Results
•The assignment of all known complete sequences up-to-date confirmed the previous six major genotypes and one new sequence, which have been provisionally assigned as subtype 7a.
•New recombinant forms of HCV, although uncommon, have been detected and were found to have different crossover points.
HIV Viral Load Predicts Risk of Infection in Large Study
HIV RNA levels are the most significant factor predicting risk of HIV transmission, according to a study reported in the February 1, 2012, Journal of Infectious Diseases. Condom use, adult male circumcision, and concurrent sexually transmitted infections (STIs) were also important factors
Detecting Staph Infections With Mass Spectrometry
Researchers have designed a new laboratory test that can quickly identify the bacterium that causes Staphylococcus aureus infections.
http://mcponline.org/content/11/1/M111.012849.abstract
Preoperative Breast Cancer Treatment May Be Improved By Combining 2 Anti-HER2 Drugs
Using two drugs that inhibit the growth factor HER2 for preoperative treatment of early-stage HER2-positive breast cancer appears to have better results than treatment with a single agent. In a report in the January 17 issue of The Lancet, an international research team reports that a protocol adding lapatinib (Tykerb) to trastuzumab (Herceptin) was more effective than single-drug treatment with either drug in eliminating microscopic signs of cancer at the time the tumors were surgically removed
http://mit.edu/urop/research/openings.html
12/15/2011
UROP Department/Lab/Center: EECS\RLE
Faculty Supervisor: Joel Voldman
Project Title: Dialysis-Like Therapeutics (DLT) for the Mitigation of Sepsis
Project Description: We are looking for an undergraduate student to help in a microfluidic project aimed to separate different types of blood cells. The microfluidic device uses electric fields to separate cells according totheir electrical properties and can be used in other applications such as cancer detection, stem cell separation, and therapeutic cell separation. The student will learn about and help with the fabrication of microfluidic devices, experimental setup design and implementation, and running experiments.
Prerequisites: Basic wet lab techniques and some familiarity with electric fields theory is helpful. This is a hands-on experimental project, so some evidence that you are good with your hands and can debug experiments is a plus.
Contact: Please send a pdf CV\resume to Joel Voldman (voldman@mit.edu) along with a paragraph in the email describing your interest in the project.
Aethlon Medical Establishes Sepsis & Inflammation Scientific Advisory Board
http://aethlonmedical.investorroom.com/index.php?s=43&item=104
Biotech Showcase™ 2012 Presentation
http://aethlonmedical.investorroom.com/index.php?s=19